全文获取类型
收费全文 | 203937篇 |
免费 | 11972篇 |
国内免费 | 589篇 |
专业分类
耳鼻咽喉 | 1052篇 |
儿科学 | 5723篇 |
妇产科学 | 7031篇 |
基础医学 | 20748篇 |
口腔科学 | 5650篇 |
临床医学 | 22154篇 |
内科学 | 35749篇 |
皮肤病学 | 2300篇 |
神经病学 | 21843篇 |
特种医学 | 9964篇 |
外国民族医学 | 2篇 |
外科学 | 24654篇 |
综合类 | 1925篇 |
现状与发展 | 7篇 |
一般理论 | 36篇 |
预防医学 | 27828篇 |
眼科学 | 3424篇 |
药学 | 11241篇 |
11篇 | |
中国医学 | 648篇 |
肿瘤学 | 14508篇 |
出版年
2024年 | 336篇 |
2023年 | 11734篇 |
2022年 | 17024篇 |
2021年 | 16803篇 |
2020年 | 18058篇 |
2019年 | 11079篇 |
2018年 | 9865篇 |
2017年 | 11441篇 |
2016年 | 11009篇 |
2015年 | 9846篇 |
2014年 | 18102篇 |
2013年 | 12908篇 |
2012年 | 7644篇 |
2011年 | 5866篇 |
2010年 | 10328篇 |
2009年 | 9271篇 |
2008年 | 3567篇 |
2007年 | 3772篇 |
2006年 | 2780篇 |
2005年 | 2093篇 |
2004年 | 1462篇 |
2003年 | 1560篇 |
2002年 | 1682篇 |
2001年 | 1690篇 |
2000年 | 1241篇 |
1999年 | 1776篇 |
1998年 | 1733篇 |
1997年 | 1361篇 |
1996年 | 1530篇 |
1995年 | 1326篇 |
1994年 | 938篇 |
1993年 | 693篇 |
1992年 | 400篇 |
1991年 | 406篇 |
1990年 | 429篇 |
1989年 | 392篇 |
1988年 | 573篇 |
1987年 | 586篇 |
1986年 | 554篇 |
1985年 | 267篇 |
1984年 | 397篇 |
1983年 | 251篇 |
1982年 | 331篇 |
1981年 | 337篇 |
1980年 | 250篇 |
1979年 | 104篇 |
1978年 | 129篇 |
1977年 | 119篇 |
1976年 | 119篇 |
1974年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
《Current problems in cardiology》2022,47(9):100902
Genistein, an isoflavone in soybean products has potential cardio-protective effects and is used also as an alternative for estrogen therapy in postmenopausal women. However, results in this regard are inconsistent and also, not all risk factors related to cardiovascular supportive effects have been meta-analyzed. We searched PubMed, Scopus, ISI Web of Science, and Google Scholar from inception up to October 2020. Random-effects meta-analysis was used for data synthesis. The search included studies with information on genistein supplementation and lipid profile [triglycerides (TG), total cholesterol (TC),low-density lipoprotein (LDL-C), and high-density lipoprotein HDL-C)], systolic and diastolic blood pressure (SBP & DBP), body mass index [BMI] and body weight. Pooled results of studies showed that genistein intake significantly reduced TC [95%CI: -0.49(-0.80, -0.18); P=0.002)], LDL-C [95%CI: -0.60(-1.10, -0.10); P=0.018)] and SBP [95%CI: -0.52(-0.90, -0.14); P=0.007)]. DBP, HLD-C, TG, BMI, and body weight showed no meaningful improvement. Subgroup analysis showed that LDL-C and SBP were reduced more effectively in postmenopausal women with metabolic syndrome. Genistein intake more than 6 months showed a greater effect on lowering cholesterol -0.76(-1.27, -0.24), SBP [-0.39(-0.70, -0.08)] and DBP -0.40(-0.81, -0.00) and increasing TG and LDL-C. This meta-analysis provides consistent evidence that genistein intake reduces the CVD risk factors of TC, LDL-C, and SBP significantly. 相似文献
142.
143.
Oxidative stress and inflammation are two possible mechanisms related to nephrotoxicity caused by environmental pollutants. Ellagic acid, a powerful antioxidant phytochemical, may have great relevance in mitigating pollutant-induced nephrotoxicity and preventing the progression of kidney disease. This review discusses the latest findings on the protective effects of ellagic acid, its metabolic derivatives, the urolithins, against kidney toxicity caused by heavy metals, pesticides, mycotoxins, and organic air pollutants. We describe the chelating, antioxidant, anti-inflammatory, antifibrotic, antiautophagic, and antiapoptotic properties of ellagic acid to attenuate nephrotoxicity. Furthermore, we present the molecular targets and signaling pathways that are regulated by these antioxidants, and suggest some others that should be explored. Nevertheless, the number of reports is still limited to establish the efficacy of ellagic acid against kidney damage induced by environmental pollutants. Therefore, additional preclinical studies on this topic are required, as well as the development of well-designed clinical trials. 相似文献
144.
145.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
146.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
147.
148.
149.
150.